GlassScriptPhysician profile
Morgan O Binder
NPI 1215676499
$8,856.66
in general payments reported to CMS, 2019-2025
33 companies · $3,727 in 2025
The $3,727 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $3,252 · 2024: $1,771 · 2025: $3,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,746 · Consulting Fee: $985 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $825 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,745.84 |
| Consulting Fee | $985.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $825.00 |
| Education | $193.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.68 | 2023-2025 | |
| Celltrion USA INC. | $1,178.54 | 2023-2025 | Zymfentra, Yuflyma |
| Takeda Pharmaceuticals U.S.A., INC. | $742.58 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $501.36 | 2022-2025 | Stelara, Tremfya |
| Lilly USA, LLC | $426.18 | 2023-2025 | Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.36 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Celgene Corporation | $339.76 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $301.15 | 2023 | |
| Genzyme Corporation | $259.22 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $249.36 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $248.74 | 2024-2025 | Tremfya |
| Redhill Biopharma INC. | $236.95 | 2023-2024 | Talicia, Movantik, Aemcolo |
| Regeneron Healthcare Solutions, INC. | $232.79 | 2022-2025 | Dupixent |
| Medtronic, INC. | $171.43 | 2024 | Interstim |
| Madrigal Pharmaceuticals | $166.73 | 2025 | Rezdiffra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $126.50 | 2025 | Dupixent |
| Qol Medical, LLC | $122.19 | 2025 | Sucraid |
| Gilead Sciences, INC. | $109.13 | 2025 | |
| Phathom Pharmaceuticals, INC. | $84.24 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $51.26 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $39.80 | 2023 | Linzess |
| Ardelyx, INC. | $38.95 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $37.15 | 2023-2024 | Clenpiq, Rebyota |
| Intercept Pharmaceuticals, INC. | $37.11 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $35.92 | 2023-2024 | Suflave |
| Merck Sharp & Dohme LLC | $32.00 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $29.47 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $28.20 | 2025 | Vowst |
| Csl Behring | $27.70 | 2023 | Kcentra |
| Daiichi Sankyo INC. | $27.25 | 2023 | Injectafer |
| Digestive Care, INC. | $25.55 | 2023 | Pertzye |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2023 | Cyltezo |
| Biocon Biologics INC | $14.59 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.